Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Robust Pipeline For Gene Therapies And Viral Vector Vaccines
3.3.1.2. Technological Advancements In Manufacturing Vectors
3.3.1.3. Highly Competitive Market And Various Strategies Undertaken By Market Entities
3.3.2. Market Restraint Analysis
3.3.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
3.3.3. Market Challenge Analysis
3.3.3.1. Production Capacity Challenges
3.3.3.2. Manufacturing Challenges Pertaining To Large Scale Production Of Vectors
3.3.4. Market Opportunity Analysis
3.3.4.1. Facility Expansion For Cell And Gene Therapies
3.4. COVID-19 Impact Analysis
3.5. Viral Vector Production: Stepwise Challenges & Solutions
3.5.1. Host Cell Production and Banking Needs
3.5.2. Viral Vector Production, F&F: Challenges & Solutions
3.5.3. Viral Vector Production, Analytics: Challenges & Solutions
3.6. Industry Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. Macroeconomic Analysis
3.7. Manufacturers Landscape
3.8. Viral Vector Production Capacity Mapping Analysis
3.8.1. North America: Capacity & Service Mapping
3.8.2. Europe: Capacity & Service Mapping
3.9. List Of Companies With Portfolio Comprising Vector-Based Therapeutic Candidates
3.10. List Of Vector Manufacturers
Chapter 4. Viral Vector Production: Costs
4.1. Cost Models For Viral Vector Production
4.1.1. Campaign Model
4.1.2. Day Rate Model
4.1.3. Hybrid Model
4.2. Viral Vectors Manufacturing Price Analysis
4.2.1. Parameters Affecting Price
4.2.2. AAV: Price Analysis
4.2.3. Lentivirus: Price Analysis
4.2.4. Adenovirus: Price Analysis
4.2.5. Retrovirus: Price Analysis
4.2.6. Plasmid: Price Analysis
4.2.7. Gene Synthesis Cost
4.2.8. Genes/ Gene Fragment Cost Analysis
Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Business Analysis
5.1. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Market Share Analysis
5.2. Viral Vectors And Plasmid DNA Manufacturing Market Estimates & Forecast, By Vector Type (USD Million)
5.3. Adenovirus
5.3.1. Global Adenovirus Market, 2018 – 2030 (USD Million)
5.4. Retrovirus
5.4.1. Global Retrovirus Market, 2018 – 2030 (USD Million)
5.5. Adeno Associated Virus (AAV)
5.5.1. Global Adeno Associated Virus (AAV) Market, 2018 – 2030 (USD Million)
5.6. Lentivirus
5.6.1. Global Lentivirus Market, 2018 – 2030 (USD Million)
5.7. Plasmids
5.7.1. Global Plasmids Market, 2018 – 2030 (USD Million)
5.8. Others
5.8.1. Global Other Vector Type Market, 2018 – 2030 (USD Million)
Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Business Analysis
6.1. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Market Share Analysis
6.2. Viral Vectors And Plasmid DNA Manufacturing Market Estimates & Forecast, By Workflow (USD Million)
6.3. Upstream Manufacturing
6.3.1. Global Upstream Manufacturing Market, 2018 – 2030 (USD Million)
6.3.2. Vector Amplification & Expansion
6.3.2.1. Global Vector Amplification & Expansion Market, 2018 – 2030 (USD Million)
6.3.3. Vector Recovery/ Harvesting
6.3.3.1. Global Vector Recovery/ Harvesting Market, 2018 – 2030 (USD Million)
6.4. Downstream Manufacturing
6.4.1. Global Downstream Manufacturing Market, 2018 – 2030 (USD Million)
6.4.2. Purification
6.4.2.1. Global Purification Market, 2018 – 2030 (USD Million)
6.4.3. Fill Finish
6.4.3.1. Global Fill Finish Market, 2018 – 2030 (USD Million)
Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: Application Business Analysis
7.1. Viral Vectors And Plasmid DNA Manufacturing Market: Application Market Share Analysis
7.2. Viral Vectors And Plasmid DNA Manufacturing Market Estimates & Forecast, By Application (USD Million)
7.3. Antisense & RNAi
7.3.1. Global Antisense & RNAi Market, 2018 – 2030 (USD Million)
7.4. Gene Therapy
7.4.1. Global Gene Therapy Market, 2018 – 2030 (USD Million)
7.5. Cell Therapy
7.5.1. Global Cell Therapy Market, 2018 – 2030 (USD Million)
7.6. Vaccinology
7.6.1. Global Vaccinology Market, 2018 – 2030 (USD Million)
7.7. Research Applications
7.7.1. Global Research Applications Market, 2018 – 2030 (USD Million)
Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: End-Use Business Analysis
8.1. Viral Vectors And Plasmid DNA Manufacturing Market: End-Use Market Share Analysis
8.2. Viral Vectors And Plasmid DNA Manufacturing Market Estimates & Forecast, By End-Use (USD Million)
8.3. Pharmaceutical & Biopharmaceutical Companies
8.3.1. Global Pharmaceutical & Biopharmaceutical Companies Market, 2018 – 2030 (USD Million)
8.4. Research Institutes
8.4.1. Global Research Institutes Market, 2018 – 2030 (USD Million)
Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Business Analysis
9.1. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Market Share Analysis
9.2. Viral Vectors And Plasmid DNA Manufacturing Market Estimates & Forecast, By Disease (USD Million)
9.3. Cancer
9.3.1. Global Cancer Market, 2018 – 2030 (USD Million)
9.4. Genetic Disorders
9.4.1. Global Genetic Disorders Market, 2018 – 2030 (USD Million)
9.5. Infectious Disease
9.5.1. Global Infectious Disease Market, 2018 – 2030 (USD Million)
9.6. Others
9.6.1. Global Others Disease Market, 2018 – 2030 (USD Million)
Chapter 10. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Business Analysis
10.1. Viral Vectors And Plasmid DNA Manufacturing Market Share By Region, 2022 & 2030
10.2. North America
10.2.1. North America Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.2.2. U.S.
10.2.2.1. Key Country Dynamics
10.2.2.2. Competitive Scenario
10.2.2.3. Regulatory Framework
10.2.2.4. U.S. Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.2.3. Canada
10.2.3.1. Key Country Dynamics
10.2.3.2. Competitive Scenario
10.2.3.3. Regulatory Framework
10.2.3.4. Canada Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.3. Europe
10.3.1. Europe Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.3.2. UK
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Framework
10.3.2.4. UK Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.3.3. Germany
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Framework
10.3.3.4. Germany Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.3.4. France
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Framework
10.3.4.4. France Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.3.5. Italy
10.3.5.1. Key Country Dynamics
10.3.5.2. Competitive Scenario
10.3.5.3. Regulatory Framework
10.3.5.4. Italy Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.3.6. Spain
10.3.6.1. Key Country Dynamics
10.3.6.2. Competitive Scenario
10.3.6.3. Regulatory Framework
10.3.6.4. Spain Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.3.7. Denmark
10.3.7.1. Key Country Dynamics
10.3.7.2. Competitive Scenario
10.3.7.3. Regulatory Framework
10.3.7.4. Denmark Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.3.8. Sweden
10.3.8.1. Key Country Dynamics
10.3.8.2. Competitive Scenario
10.3.8.3. Regulatory Framework
10.3.8.4. Sweden Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.3.9. Norway
10.3.9.1. Key Country Dynamics
10.3.9.2. Competitive Scenario
10.3.9.3. Regulatory Framework
10.3.9.4. Norway Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.4. Asia Pacific
10.4.1. Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.4.2. Japan
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Framework
10.4.2.4. Japan Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.4.3. China
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Framework
10.4.3.4. China Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.4.4. India
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Framework
10.4.4.4. India Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.4.5. Australia
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Regulatory Framework
10.4.5.4. Australia Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.4.6. South Korea
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Regulatory Framework
10.4.6.4. South Korea Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.4.7. Thailand
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Regulatory Framework
10.4.7.4. Thailand Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.5. Latin America
10.5.1. Latin America Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.5.2. Brazil
10.5.2.1. Key Country Dynamics
10.5.2.2. Competitive Scenario
10.5.2.3. Regulatory Framework
10.5.2.4. Brazil Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.5.3. Mexico
10.5.3.1. Key Country Dynamics
10.5.3.2. Competitive Scenario
10.5.3.3. Regulatory Framework
10.5.3.4. Mexico Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.5.4. Argentina
10.5.4.1. Key Country Dynamics
10.5.4.2. Competitive Scenario
10.5.4.3. Regulatory Framework
10.5.4.4. Argentina Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.6. MEA
10.6.1. MEA Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.6.2. South Africa
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Regulatory Framework
10.6.2.4. South Africa Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.6.3. Saudi Arabia
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Regulatory Framework
10.6.3.4. Saudi Arabia Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.6.4. UAE
10.6.4.1. Key Country Dynamics
10.6.4.2. Competitive Scenario
10.6.4.3. Regulatory Framework
10.6.4.4. UAE Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
10.6.5. Kuwait
10.6.5.1. Key Country Dynamics
10.6.5.2. Competitive Scenario
10.6.5.3. Regulatory Framework
10.6.5.4. Kuwait Viral Vectors And Plasmid DNA Manufacturing Market, 2018 – 2030 (USD Million)
Chapter 11. Competitive Landscape
11.1. Company Categorization
11.2. Strategy Mapping
11.3. Company Profiles/Listing
11.3.1. Merck KGaA
11.3.1.1. Overview
11.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.1.3. Product Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Lonza
11.3.2.1. Overview
11.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.2.3. Product Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. FUJIFILM Diosynth Biotechnologies
11.3.3.1. Overview
11.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.3.3. Product Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. Thermo Fisher Scientific
11.3.4.1. Overview
11.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.4.3. Product Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. Cobra Biologics
11.3.5.1. Overview
11.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.5.3. Product Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. Catalent Inc.
11.3.6.1. Overview
11.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.6.3. Product Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. Wuxi Biologics
11.3.7.1. Overview
11.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.7.3. Product Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. Takara Bio Inc.
11.3.8.1. Overview
11.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.8.3. Product Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Waisman Biomanufacturing
11.3.9.1. Overview
11.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.9.3. Product Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. Genezen Laboratories
11.3.10.1. Overview
11.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.10.3. Product Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. Batavia Biosciences
11.3.11.1. Overview
11.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.11.3. Product Benchmarking
11.3.11.4. Strategic Initiatives
11.3.12. Miltenyi Biotec GmBH
11.3.12.1. Overview
11.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.12.3. Product Benchmarking
11.3.12.4. Strategic Initiatives
11.3.13. SIRION Biotech GmBH
11.3.13.1. Overview
11.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.13.3. Product Benchmarking
11.3.13.4. Strategic Initiatives
11.3.14. Virovek Incorporation
11.3.14.1. Overview
11.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.14.3. Product Benchmarking
11.3.14.4. Strategic Initiatives
11.3.15. BioNTech IMFS GmBh
11.3.15.1. Overview
11.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.15.3. Product Benchmarking
11.3.15.4. Strategic Initiatives
11.3.16. Audentes Therapeutics
11.3.16.1. Overview
11.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.16.3. Product Benchmarking
11.3.16.4. Strategic Initiatives
11.3.17. BioMarin Pharmaceutical
11.3.17.1. Overview
11.3.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.17.3. Product Benchmarking
11.3.17.4. Strategic Initiatives
11.3.18. RegenxBio, Inc.
11.3.18.1. Overview
11.3.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.3.18.3. Product Benchmarking
11.3.18.4. Strategic Initiatives
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 4 Global Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 5 Global Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 6 Global Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 7 Global Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 8 Global Viral Vectors And Plasmid DNA Manufacturing market, by region, 2018 - 2030 (USD Million)
Table 9 North America Viral Vectors And Plasmid DNA Manufacturing market, by country, 2018 - 2030 (USD Million)
Table 10 North America Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 11 North America Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 12 North America Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 13 North America Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 14 North America Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 15 U.S. Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 16 U.S. Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 17 U.S. Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 18 U.S. Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 19 U.S. Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 20 Canada Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 21 Canada Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 22 Canada Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 23 Canada Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 24 Canada Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 25 Europe Viral Vectors And Plasmid DNA Manufacturing market, by country, 2018 - 2030 (USD Million)
Table 26 Europe Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 27 Europe Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 28 Europe Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 29 Europe Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 30 Europe Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 31 Germany Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 32 Germany Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 33 Germany Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 34 Germany Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 35 Germany Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 36 UK Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 37 UK Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 38 UK Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 39 UK Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 40 UK Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 41 France Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 42 France Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 43 France Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 44 France Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 45 France Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 46 Italy Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 47 Italy Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 48 Italy Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 49 Italy Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 50 Italy Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 51 Spain Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 52 Spain Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 53 Spain Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 54 Spain Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 55 Spain Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 56 Denmark Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 57 Denmark Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 58 Denmark Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 59 Denmark Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 60 Denmark Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 61 Sweden Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 62 Sweden Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 63 Sweden Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 64 Sweden Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 65 Sweden Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 66 Norway Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 67 Norway Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 68 Norway Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 69 Norway Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 70 Norway Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 71 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing market, by country, 2018 - 2030 (USD Million)
Table 72 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 73 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 74 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 75 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 76 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 77 Japan Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 78 Japan Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 79 Japan Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 80 Japan Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 81 Japan Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 82 China Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 83 China Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 84 China Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 85 China Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 86 China Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 87 India Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 88 India Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 89 India Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 90 India Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 91 India Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 92 Australia Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 93 Australia Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 94 Australia Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 95 Australia Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 96 Australia Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 97 South Korea Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 98 South Korea Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 99 South Korea Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 100 South Korea Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 101 South Korea Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 102 Thailand Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 103 Thailand Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 104 Thailand Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 105 Thailand Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 106 Thailand Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 107 Latin America Viral Vectors And Plasmid DNA Manufacturing market, by country, 2018 - 2030 (USD Million)
Table 108 Latin America Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 109 Latin America Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 110 Latin America Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 111 Latin America Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 112 Latin America Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 113 Brazil Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 114 Brazil Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 115 Brazil Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 116 Brazil Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 117 Brazil Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 118 Mexico Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 119 Mexico Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 120 Mexico Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 121 Mexico Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 122 Mexico Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 123 Argentina Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 124 Argentina Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 125 Argentina Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 126 Argentina Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 127 Argentina Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 128 Middle East & Africa Viral Vectors And Plasmid DNA Manufacturing market, by country, 2018 - 2030 (USD Million)
Table 129 Middle East & Africa Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 130 Middle East & Africa Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 131 Middle East & Africa Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 132 Middle East & Africa Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 133 Middle East & Africa Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 134 South Africa Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 135 South Africa Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 136 South Africa Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 137 South Africa Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 138 South Africa Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 139 Saudi Arabia Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 141 Saudi Arabia Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 142 Saudi Arabia Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 143 Saudi Arabia Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 144 UAE Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 145 UAE Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 146 UAE Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 147 UAE Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 148 UAE Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 149 Kuwait Viral Vectors And Plasmid DNA Manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 150 Kuwait Viral Vectors And Plasmid DNA Manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 151 Kuwait Viral Vectors And Plasmid DNA Manufacturing market, by application, 2018 - 2030 (USD Million)
Table 152 Kuwait Viral Vectors And Plasmid DNA Manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 153 Kuwait Viral Vectors And Plasmid DNA Manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 154 Participant's overview
Table 155 Financial performance
Table 156 Key companies undergoing expansions
Table 157 Key companies undergoing acquisitions
Table 158 Key companies undergoing collaborations
Table 159 Key companies launching new vector types/services
Table 160 Key companies undertaking other strategies
